Reilly R Kayser1,2, Margaret Haney1,2, Marissa Raskin2, Caroline Arout1,2, Helen Blair Simpson1,2. 1. Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, New York. 2. Office of Mental Health, Research Foundation for Mental Hygiene, New York State Psychiatric Institute, New York, New York.
Abstract
BACKGROUND: Preclinical data implicate the endocannabinoid system in the pathology underlying obsessive-compulsive disorder (OCD), while survey data have linked OCD symptoms to increased cannabis use. Cannabis products are increasingly marketed as treatments for anxiety and other OCD-related symptoms. Yet, few studies have tested the acute effects of cannabis on psychiatric symptoms in humans. METHODS: We recruited 14 adults with OCD and prior experience using cannabis to enter a randomized, placebo-controlled, human laboratory study to compare the effects on OCD symptoms of cannabis containing varying concentrations of Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on OCD symptoms to placebo. We used a within-subjects design to increase statistical power. Across three laboratory sessions, participants smoked three cannabis varietals in random order: placebo (0% THC/0% CBD); THC (7.0% THC/0.18% CBD); and CBD (0.4% THC/10.4% CBD). We analyzed acute changes in OCD symptoms, state anxiety, cardiovascular measures, and drug-related effects (e.g., euphoria) as a function of varietal. RESULTS: Twelve participants completed the study. THC increased heart rate, blood pressure, and intoxication compared with CBD and placebo. Self-reported OCD symptoms and anxiety decreased over time in all three conditions. Although OCD symptoms did not vary as a function of cannabis varietal, state anxiety was significantly lower immediately after placebo administration relative to both THC and CBD. CONCLUSIONS: This is the first placebo-controlled investigation of cannabis in adults with OCD. The data suggest that smoked cannabis, whether containing primarily THC or CBD, has little acute impact on OCD symptoms and yields smaller reductions in anxiety compared to placebo.
BACKGROUND: Preclinical data implicate the endocannabinoid system in the pathology underlying obsessive-compulsive disorder (OCD), while survey data have linked OCD symptoms to increased cannabis use. Cannabis products are increasingly marketed as treatments for anxiety and other OCD-related symptoms. Yet, few studies have tested the acute effects of cannabis on psychiatric symptoms in humans. METHODS: We recruited 14 adults with OCD and prior experience using cannabis to enter a randomized, placebo-controlled, human laboratory study to compare the effects on OCD symptoms of cannabis containing varying concentrations of Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on OCD symptoms to placebo. We used a within-subjects design to increase statistical power. Across three laboratory sessions, participants smoked three cannabis varietals in random order: placebo (0% THC/0% CBD); THC (7.0% THC/0.18% CBD); and CBD (0.4% THC/10.4% CBD). We analyzed acute changes in OCD symptoms, state anxiety, cardiovascular measures, and drug-related effects (e.g., euphoria) as a function of varietal. RESULTS: Twelve participants completed the study. THC increased heart rate, blood pressure, and intoxication compared with CBD and placebo. Self-reported OCD symptoms and anxiety decreased over time in all three conditions. Although OCD symptoms did not vary as a function of cannabis varietal, state anxiety was significantly lower immediately after placebo administration relative to both THC and CBD. CONCLUSIONS: This is the first placebo-controlled investigation of cannabis in adults with OCD. The data suggest that smoked cannabis, whether containing primarily THC or CBD, has little acute impact on OCD symptoms and yields smaller reductions in anxiety compared to placebo.
Authors: R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross Journal: Pharmacol Rev Date: 2010-12 Impact factor: 25.468
Authors: Amedeo Minichino; Morwenna Senior; Natascia Brondino; Sam H Zhang; Beata R Godwlewska; Philip W J Burnet; Andrea Cipriani; Belinda R Lennox Journal: JAMA Psychiatry Date: 2019-09-01 Impact factor: 21.596
Authors: Felipe V Gomes; Plinio C Casarotto; Leonardo B M Resstel; Francisco S Guimarães Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-11-25 Impact factor: 5.067
Authors: N C R McLaughlin; D Strong; A Abrantes; S Garnaat; A Cerny; C O'Connell; R Fadok; C Spofford; S A Rasmussen; M R Milad; B D Greenberg Journal: Behav Brain Res Date: 2014-11-12 Impact factor: 3.332
Authors: Leah M Mayo; Anna Asratian; Johan Lindé; Maria Morena; Roosa Haataja; Valter Hammar; Gaëlle Augier; Matthew N Hill; Markus Heilig Journal: Biol Psychiatry Date: 2019-08-13 Impact factor: 13.382
Authors: Margaret Haney; Ziva D Cooper; Gillinder Bedi; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin Journal: Neuropsychopharmacology Date: 2013-02-26 Impact factor: 7.853
Authors: Demitri F Papolos; Martin H Teicher; Gianni L Faedda; Patricia Murphy; Steven Mattis Journal: J Affect Disord Date: 2012-11-30 Impact factor: 4.839
Authors: Chandni Hindocha; Tom P Freeman; Grainne Schafer; Chelsea Gardener; Ravi K Das; Celia J A Morgan; H Valerie Curran Journal: Eur Neuropsychopharmacol Date: 2014-12-05 Impact factor: 4.600
Authors: Toni C Spinella; Sherry H Stewart; Julia Naugler; Igor Yakovenko; Sean P Barrett Journal: Psychopharmacology (Berl) Date: 2021-04-04 Impact factor: 4.530